Capitalization 643M 425M P/E ratio 2024 *
-35.5x
P/E ratio 2025 * -
Enterprise value 171M 113M EV / Sales 2024 *
709x
EV / Sales 2025 * 16.3x
Free-Float
85.28%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.39%
1 week-7.79%
Current month+2.90%
1 month-5.33%
3 months+65.12%
6 months+115.15%
Current year+86.84%
More quotes
1 week
0.34
Extreme 0.342
0.41
1 month
0.31
Extreme 0.305
0.41
Current year
0.16
Extreme 0.162
0.41
1 year
0.12
Extreme 0.115
0.41
3 years
0.05
Extreme 0.052
0.41
5 years
0.02
Extreme 0.023
0.41
10 years
0.02
Extreme 0.023
0.41
More quotes
Manager TitleAgeSince
Chief Executive Officer - 19-04-30
Director of Finance/CFO - Mar. 25
Chairman 65 19-05-19
Director TitleAgeSince
Director/Board Member - 16-06-30
Director/Board Member 54 19-02-20
Chairman 65 19-05-19
More insiders

Specialty & Advanced Pharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-1.39%-7.79%+153.57%+355.13% 433M
+2.13%-0.62%-2.86%-12.01% 70.98B
+0.85%+2.93%+18.38%-14.15% 10.66B
+1.15%-0.72%+51.23%+81.64% 5.2B
-1.27%+4.28%-0.12%-31.21% 4.81B
0.00%-8.43%+54.76%+149.67% 3.38B
+1.71%+0.64%+17.48%+27.55% 2.3B
+1.30%+2.66%-35.61%-65.58% 1.84B
+0.39%+2.24%-48.31%-67.72% 1.74B
-0.02%+3.90%+0.07%+10.27% 1.65B
Average +0.48%+0.64%+20.86%+43.36% 10.3B
Weighted average by Cap. +1.62%-0.37%+3.90%-2.21%
See all sector performances
Ratios2024 *2025 *
Net sales 800K 529K 35.6M 23.55M
Net income -11.7M -7.74M 3.6M 2.38M
Net Debt -75.6M -50.01M -63.7M -42.14M
More financial data * Estimated data
Logo Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.
Employees
0
More about the company
Date Price Change Volume
24-07-23 0.3550 $ -1.39% 4 721 936
24-07-22 0.3600 $ -2.70% 7,985,448
24-07-19 0.3700 $ -2.63% 8,277,670
24-07-18 0.3800 $ -3.80% 9,104,302
24-07-17 0.3950 $ +2.60% 12,296,850

Delayed Quote Australian S.E., July 23, 2024 at 02:10 am EDT

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3600AUD
Average target price
0.5500AUD
Spread / Average Target
+52.78%
Consensus

Annual profits - Rate of surprise